Ideaya Going to Present IDE397 Phase 1 Expansion Results at EORTC-NCI-AACR Symposium

Ideaya Going to Present IDE397 Phase 1 Expansion Results at EORTC-NCI-AACR Symposium

By, Admin 7 October 2024

Ideaya Biosciences to present IDE397 phase 1 expansion results in MTAP-deletion lung and urothelial cancer at EORTC-NCI-AACR symposium

Overview

Ideaya Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of the phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor in methylthioadenosine phosphorylase (MTAP)-deletion urothelial and non-small cell lung cancer (NSCLC) patients at the 36th edition of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place on October 23 to 25, 2024, in Barcelona, Spain.  In addition, Ideaya will also have additional poster presentations at the EORTC-NCI-AACR Symposium highlighting preclinical data for the MAT2A and PARG programmes.

About the presentation

Details for The Oral Presentation are: 

  • Presenter: Dr. Benjamin Herzberg, MD, Assistant Professor, Columbia University
  • Title: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC) 
  • Abstract #: 501 LBA
  • Session: Plenary Session 7
  • Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug development 
  •  Date and Time: Friday, October 25, 2024 at 3:00pm CEST.

Poster Presentation Details are: 

  • Author: Garbett, D. et al. 
  • Title: The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumours 
  • Poster Number: PB204 
  • Session Title: Combination Therapies
  • Date and Time: Thursday, October 24, 2024, 9:00am - 5:30pm CEST, Exhibition Hall.
  • Author: Munoz, D. et al. 
  • Title: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets solid tumours with replication stress and DNA repair vulnerabilities
  • Poster Number: PB337 
  • Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM) 
  • Date and Time: Friday, October 25, 2024, 9:00am - 3:00pm CEST, Exhibition Hall.

About the Company: Ideaya Biosciences, Inc.

Ideaya is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!